Use of mycophenolate mofetil in inflammatory bowel disease

Table 1 Demographics of the IBD patients using the Montreal classification

	CD patients n = 9	UC/IBDU patients n = 5
Gender: male	57.1% (8/14)	57.1% (8/14)
Age at diagnosis
Mean ± SE (range)	38.6 ± 13.3 yr (19-54)	44.0 ± 12.7 yr (30-63)
A1- ≤ 16	0% (0/9)	0% (0/5)
A2-17-40	44.4% (4/9)	40% (2/5)
A3- > 40	55.6% (5/9)	60% (3/5)
Disease duration
Mean (range)	10.4 yr (1-26)	9.8 yr (1-28)
Crohn’s disease
L1-terminal ileum	22.2% (2/9)
L2-colon	33.3% (3/9)
L3-ileocolonic	44.4% (4/9)
L4-upper GI	11.1% (1/9)
P-perianal	22.2% (2/9)
B1-inflammatory	44.4% (4/9)
B2-stricturing	33.3% (3/9)
B3-perforating	22.2% (2/9)
Ulcerative colitis/IBDU
E1-proctitis		20% (1/5)
E2-left sided		40% (2/5)
E3-extensive		40% (2/5)
Raised CRP	55.6% (5/9)	80.0% (4/5)

Table 2 Medications taken by study patients at time of the commencement of MMF therapy

	CD patients n = 9	UC/IBDU patients n = 5
5-ASA
Current	88.9% (8/9)	100% (5/5)
Steroids
Current	55.5% (5/9)	100% (5/5)
Intolerant	22.2% (2/9)	0%
AZA/6MP
Intolerant	88.8% (8/9)	100% (5/5)
Methotrexate
Ineffective	33.3% (3/9)	N/A
Intolerant	11.1% (1/9)
Refused	33.3% (3/9)
Antibiotics
Ineffective	33.3% (3/9)	N/A
Intolerant	11.1% (1/9)
Infliximab
Current	0%	0%
Ineffective	44.4% (4/9)	40% (2/5)
Intolerant	22.2% (2/9)	0%

N/A: Not applicable.

Table 3 Response and remission rates at 8 wk and CRP levels with MMF therapy

	CD patients n = 9	UC/IBDU patients n = 5
emission	66.7% (6/9)	80% (4/5)
Response	66.7% (6/9)	80% (4/5)
Intolerant	22.2% (2/9)	20% (1/5)
Ineffective	11.1% (1/9)	0% (0/5)
Raised CRP
In responders	0% (0/6)	0% (4/5)
In non ponders	33.3% (1/3)	100% (1/1)

Table 4 Individual patient data of disease extent, age at treatment, duration of MMF therapy and response

	Sex	Diagnosis	Age at diagnosis	Age at MMF	Indication for MMF	Disease extent	Duration of MMF (mo)	Response after 8 wk	Steroids continued at 8 wk
1	M	CD	27	28	Steroid dependant	Pancolitis	30	Remission	Ceased
2	M	CD	54	55	Steroid dependant	L Sided colitis/fistula	12	Remission	Ceased
3	F	CD	50	67	Severe Psoriasis	Ileocolonic disease	48	Remission	N/A
4	M	CD	41	41	Steroid dependant	Ileocolonic disease	12	Remission	Ceased
5	M	CD	53	63	Recurrent TI resections	Recurrent ileal disease	15	Remission	N/A
6	F	CD	32	58	Steroid intolerant	Colectomy/2x TI resection/recurrent ileal disease	< 1	Intolerant	Continued
7	F	CD	19	28	Steroid dependant	Subtotal colectomy/recurrent ileal disease/fistula	< 1	Intolerant	Continued
8	M	CD	21	48	Steroid dependant	Ileal disease	6	Ineffective	Surgery
9	F	UC/IBDU	43	50	Steroid dependant	Pancolitis	12	Remission	Ceased
10	M	UC/IBDU	31	33	Steroid dependant	L Sided colitis	9	Remission	Ceased
11	M	UC/IBDU	53	64	Steroid dependant	L Sided colitis	22	Remission	Ceased
12	F	CD	50	50	Recurrent flares	Pancolitis	12	Remission	Ceased
13	M	UC/IBDU	63	63	Steroid dependant	Pancolitis	8	Remission	Ceased
14	F	UC/IBDU	30	58	Steroid dependant	Subtotal colectomy/proctitis	< 1	Intolerant	Continued